Expertise in
22
conditions

Dr. Zachary Zumsteg

Radiation Oncology
Cedars-Sinai Radiation Oncology-Los Angeles
8720 Beverly Blvd, 
West Hollywood, CA 
Offers Telehealth
Expertise in
22
conditions
Cedars-Sinai Radiation Oncology-Los Angeles
8720 Beverly Blvd, 
West Hollywood, CA 

Overview

Zachary Zumsteg is a Radiation Oncologist in West Hollywood, California. Dr. Zumsteg is highly rated in 22 conditions, according to our data. His top areas of expertise are Prostate Cancer, Laryngeal Cancer, Throat Cancer, Prostatectomy, and Thyroidectomy.

His clinical research consists of co-authoring 130 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Radiation Oncology

Hospital Affiliations

Cedars-Sinai Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Cedars-Sinai Radiation Oncology-Los Angeles
8720 Beverly Blvd, West Hollywood, CA 90048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Radiation, Procedure
Study Phase: Early Phase 1
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
View 7 Less Clinical Trials

130 Total Publications

Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium.
Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium.
Journal: JCO oncology practice
Published: December 04, 2025
Similar Doctors
Expertise in
21
conditions
Dr. Mitchell Kamrava
Radiation Oncology
Expertise in
21
conditions
Dr. Mitchell Kamrava
Radiation Oncology

Cedars-Sinai Radiation Oncology-Los Angeles

8720 Beverly Blvd, 
West Hollywood, CA 
 (0.1 miles away)
310-423-4208
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mitchell Kamrava is a Radiation Oncologist in West Hollywood, California. Dr. Kamrava is highly rated in 21 conditions, according to our data. His top areas of expertise are Cervical Cancer, Vaginal Cancer, Prostate Cancer, Prostatectomy, and Vitrectomy.

Expertise in
7
conditions
Dr. Amar Kishan
Radiation Oncology
Expertise in
7
conditions
Dr. Amar Kishan
Radiation Oncology

UCLA Thoracic Surgery 200 Medical Plaza

200 UCLA Medical Plz Ste B265, 
Los Angeles, CA 
 (3.6 miles away)
310-825-9771
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amar Kishan is a Radiation Oncologist in Los Angeles, California. Dr. Kishan is highly rated in 7 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Prostatectomy, and Bone Marrow Aspiration.

Expertise in
35
conditions
Dr. Tania Kaprealian
Radiation Oncology
Expertise in
35
conditions
Dr. Tania Kaprealian
Radiation Oncology

UCLA Thoracic Surgery 200 Medical Plaza

200 UCLA Medical Plz Ste B265, 
Los Angeles, CA 
 (3.6 miles away)
310-825-9775
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tania Kaprealian is a Radiation Oncologist in Los Angeles, California. Dr. Kaprealian is highly rated in 35 conditions, according to our data. Her top areas of expertise are Meningioma, Schwannoma, Radiation Induced Meningioma, Acoustic Neuroma, and Thalamotomy.

Frequently Asked Questions about Dr. Zachary Zumsteg

How do I make an appointment with Dr. Zachary Zumsteg?

You can book an appointment with Dr. Zachary Zumsteg by calling their office at 310-423-4208. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Zachary Zumsteg a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Zachary Zumsteg is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Zachary Zumsteg specialize in?

While Dr. Zachary Zumsteg is a Radiation Oncology, they have specific expertise in Prostate Cancer, Laryngeal Cancer, and Throat Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Zachary Zumsteg participate in research or clinical trials?

Yes. Dr. Zachary Zumsteg has published 130 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Zachary Zumsteg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Zachary Zumsteg accept my insurance?

Dr. Zachary Zumsteg accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 310-423-4208 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zumsteg's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile